HR-positive, HER2-negative Breast Neoplasms
1 clinical trials · Condition
◉ Watch HR-positive, HER2-negative Breast Neoplasms
| Record | Firm | Date |
|---|---|---|
| To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer (NCT05365178) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-07-01 |
Track HR-positive, HER2-negative Breast Neoplasms automatically
Every clearance here is in the API, with alerts when new ones post.